The Uromigos
The Uromigos
Advertisement
The UromigosThe Uromigos | February 26, 2024
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
Listen Now
The UromigosThe Uromigos | February 26, 2024
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
The UromigosThe Uromigos | February 12, 2024
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
The UromigosThe Uromigos | February 7, 2024
Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer.
The UromigosThe Uromigos | February 2, 2024
Reviewing the top presentations from ASCO GU 2024, including the phase III GETUG-AFU-18 study, CONTACT-02, and more.
The UromigosThe Uromigos | January 30, 2024
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
The UromigosThe Uromigos | January 30, 2024
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
The UromigosThe Uromigos | January 30, 2024
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
The UromigosThe Uromigos | January 30, 2024
Andrea Apolo, MD, discusses the phase III AMBASSADOR study that investigated adjuvant pembrolizumab against observation.
The UromigosThe Uromigos | January 30, 2024
Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024.
The UromigosThe Uromigos | January 30, 2024
Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer.
The UromigosThe Uromigos | January 30, 2024
Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer. ...
The UromigosThe Uromigos | January 30, 2024
The Uromigos discuss the presentations to look out for at this year's ASCO Genitourinary Cancers Symposium.
The UromigosThe Uromigos | January 30, 2024
Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature.
The UromigosThe Uromigos | January 11, 2024
Thomas Zilli joins the podcast to talk about the controversies surrounding radiotherapy for prostate cancer.
The UromigosThe Uromigos | January 11, 2024
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue at APCCC 2024.
The UromigosThe Uromigos | January 11, 2024
Silke Gillessen gives an overview of APCCC 2024 taking place in Lugano, Switzerland, in April.
The UromigosThe Uromigos | January 11, 2024
Cristina Suarez discusses the biggest RCC trials of 2023.
The UromigosThe Uromigos | January 11, 2024
Elena Castro, Begoña Valerrama and Cristina Suárez analyze some of the urothelial carcinoma research highlights of 2023.
The UromigosThe Uromigos | December 20, 2023
The Uromigos close out the year with Tanya Dorff, MD, as she discusses her favorite prostate cancer studies of 2023.
Advertisement
Advertisement
Advertisement